Payment overview · 2025
General Payments
$248.92
14 reported records · 7 companies
Healthcare provider profile · identity verified
Stanley Mark Swindell, MD
Allopathic & Osteopathic Physicians|Emergency Medicine · ONEIDA, TN · NPI 1770530669
Verified facts
What the public records show
CMS Open Payments records show Stanley Mark Swindell, MD received $248.92 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.54 | 35.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.71 | 24.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.87 | 16.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.69 | 6.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.11 | 6.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.27 | 5.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.73 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.92 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $87.54 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.71 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.87 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.27 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 211 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
211 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 633 | 77 |
| Oxycodone Hcl | Oxycodone Hcl | 588 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 478 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 464 | 94 |
| Omeprazole | Omeprazole | 344 | 76 |
| Lisinopril | Lisinopril | 259 | 72 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 246 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 52 |
| Ozempic | Semaglutide | 211 | 33 |
| Alprazolam | Alprazolam | 210 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 202 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 45 |
| Clonazepam | Clonazepam | 161 | 21 |
| Furosemide | Furosemide | 158 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 149 | 46 |
| Metformin Hcl | Metformin Hcl | 149 | 33 |
| Trazodone Hcl | Trazodone Hcl | 147 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 32 |
| Prednisone | Prednisone | 137 | 70 |
| Montelukast Sodium | Montelukast Sodium | 134 | 28 |
| Meloxicam | Meloxicam | 129 | 31 |
| Ezetimibe | Ezetimibe | 128 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 37 |
| Eliquis | Apixaban | 118 | 28 |
| Ondansetron Odt | Ondansetron | 110 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 22 |
| Buspirone Hcl | Buspirone Hcl | 100 | 22 |
| Jardiance | Empagliflozin | 100 | 20 |
| Pregabalin | Pregabalin | 99 | 13 |
| Losartan Potassium | Losartan Potassium | 95 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 20 |
| Ibuprofen | Ibuprofen | 80 | 25 |
| Linzess | Linaclotide | 78 | 17 |
| Potassium Chloride | Potassium Chloride | 76 | 19 |
| Farxiga | Dapagliflozin Propanediol | 74 | 17 |
| Metformin Hcl Er | Metformin Hcl | 66 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 48 |
| Clonidine Hcl | Clonidine Hcl | 64 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 17 |
| Allopurinol | Allopurinol | 62 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 17 |
| Carvedilol | Carvedilol | 55 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | 12 |
| Promethazine Hcl | Promethazine Hcl | 54 | 15 |
| Famotidine | Famotidine | 50 | 13 |
| Fluconazole | Fluconazole | 50 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 35 |
| Chlorthalidone | Chlorthalidone | 47 | 13 |
| Cefdinir | Cefdinir | 46 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 38 | 29 |
| Spironolactone | Spironolactone | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 34 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 23 |
| Meclizine Hcl | Meclizine Hcl | 32 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | 11 |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 18 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Risperidone | Risperidone | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Atenolol | Atenolol | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 12 |
| Simvastatin | Simvastatin | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 13 |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $248.92 · 14 records | ABBVIE INC. | CAPLYTA, FARXIGA, Kerendia, Ozempic, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error